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Sternbergh, MD, Ochsner Clinic, New Orleans, La.INVITED COMMENTARYMagruder C. Donaldson, MD, Boston, MassThe strengths of this multicenter prospective trial comparing
bare nitinol stents to polytetraﬂuoroethylene stent grafts for Trans-
Atlantic Inter-Society Consensus 1 C and D superﬁcial femoral
artery lesions include an uncommon effort to standardize method-
ology and an uncommon glimpse at 3-year outcomes. The inves-
tigators are to be commended for attempting to drive a guidepost
into the riverbed and refusing to go with the ﬂow, simply assuming
that any decent study will be outdated by intercurrent innovations
such as drug-eluting stents and heparin-bonded stent grafts.
The study tests the reasonable hypothesis that covered stents
would eliminate in-stent restenosis, a chief cause of nitinol stent
failure. Though the patency comparisons at 3 years suffer from
some attrition of patients with cautionary wobble in the Kaplan-
Meier curves, there was no apparent patency advantage to stent
grafts. The reader remains intrigued by the lack of details regarding
the ultrasound and angiographic lesions responsible for device
failure, which given the surveillance protocol and high rate of rein-
tervention, must have been available to allow distinction between
intimal hyperplasia at the stent margins or within the stents and
progression of disease in untreated adjacent arterial segments.
Among patients followed for 36 months, the stent fracture rate
was 50% for nitinol stents and only 2% for stent grafts.Acknowledging that the impact of stent fracture is controversial,
if one assumes a negative impact of fracture on nitinol stent
patency and a positive impact of less in-stent restenosis on stent
graft patency, we might have expected an unequivocal patency
advantage for stent grafts rather than the somewhat disappointing
equivalency between the two groups. If indeed nitinol stents and
stent grafts do have similar efﬁcacy, device cost would assume
more importance in the current penny-pinching era.
Comparison of trial results with surgical bypass is invalidated
by randomization of patients only after lesions had been crossed
by a guidewire. Nonetheless, optimal results at 3 years were
attained only after one or more reinterventions in 40% of patients,
a much higher rate than might be expected in a series of superﬁcial
femoral artery bypasses. Again, costs need consideration.
The study employed somewhat confusing patency deﬁnitions
unfamiliar to most surgeons accustomed to tracking bypass grafts.
Development of standards for reporting has been one of the signal
contributions to vascular surgery over the years, and we must
extend this effort to the endovascular arena, including our
colleagues in related subspecialties. Only by adopting uniform
research methodology can we build fruitfully on earnest efforts
such as those of the VIBRANT trial team.
